Media contributions
1Media contributions
Title Almac Group Awarded US patent for Ground-breaking DDRD Assay Degree of recognition International Media name/outlet Applied Clinical Trials Media type Print Country/Territory United Kingdom Date 30/05/2017 Description Almac Group’s announced it has been granted U.S. patent protection for its DNA Damage Response Deficiency (DDRD) assay. The patent numbers issued are 9,670,547 and 9,677,140, each titled Molecular Diagnostic Test for Cancer, and are effective until 2031 URL www.appliedclinicaltrialsonline.com/latest-business-and-people-news-11 Persons Paul Harkin